Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 4/20 | 1.00 |
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | GMNN | O75496 | 3/20 | 1.00 |
| ▸ | POLB | P06746 | 3/20 | 1.00 |
| ▸ | BLM | P54132 | 3/20 | 1.00 |
| ▸ | CETP | P11597 | 3/20 | 1.00 |
| ▸ | UBE2N | P61088 | 3/20 | 1.00 |
| ▸ | THPO | P40225 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | GLA | P06280 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Safingol SCHEMBL5061324 | 1.00 | CYP2D6 (1.00) | CYP2D6SPHK1LMNAMAPTGMNN | |
| SCHEMBL1900812 | 1.00 | CYP2D6 (1.00) | CYP2D6SPHK1LMNAMAPTGMNN | |
| Safingol SCHEMBL6772 | 1.00 | CYP2D6 (1.00) | CYP2D6SPHK1LMNAMAPTGMNN | |
| SCHEMBL1131930 | 1.00 | CYP2D6 (1.00) | CYP2D6SPHK1LMNAMAPTGMNN | |
| SCHEMBL16455713 | 1.00 | CYP2D6 (1.00) | CYP2D6SPHK1LMNAMAPTGMNN | |
| SCHEMBL12330738 | 1.00 | CYP2D6 (1.00) | CYP2D6SPHK1LMNAMAPTGMNN | |
| SCHEMBL1131985 | 1.00 | CYP2D6 (1.00) | CYP2D6SPHK1LMNAMAPTGMNN | |
| SCHEMBL21660227 | 1.00 | CYP2D6 (1.00) | CYP2D6SPHK1LMNAMAPTGMNN | |
| SCHEMBL21431064 | 1.00 | CYP2D6 (1.00) | CYP2D6SPHK1LMNAMAPTGMNN | |
| SCHEMBL18127645 | 1.00 | CYP2D6 (1.00) | CYP2D6SPHK1LMNAMAPTGMNN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210015767-A1 | ARTIFICIALLY SYNTHESIZED SPHINGOSINE DERIVATIVE LIPOID MONOMER AND USE OF SAME FOR DELIVERING NUCLEIC ACID | BEIJING BAISHIHEKANG PHARMACEUTICAL TECHNOLOGY (BSJPHARMA) CO., LTD (CN) | 2021-01-21 | — | — | US | disclosed |
| WO-2014118556-A2 | SELECTIVE INHIBITORS AND ALLOSTERIC ACTIVATORS OF SPHINGOSINE KINASE | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2014-08-07 | — | — | WO | disclosed |
| US-20110150984-A1 | METHODS OF INCREASING THE BIOAVAILABILITY AND/OR CELLULAR UPDATE OF DRUGS | HET NEDERLANDS KANKER INSTITUUT (NL) | 2011-06-23 | — | — | US | disclosed |
| US-7915227-B2 | Pharmaceutical formulations employing short-chain sphingolipids and their use | HET NEDERLANDS KANKER INSTITUUT (NL) | 2011-03-29 | — | — | US | disclosed |
| US-20070082855-A1 | Pharmaceutical formulations employing short-chain sphingolipids and their use | HET NEDERLANDS KANKER INSTITUUT (NL) | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210015767-A1 | ARTIFICIALLY SYNTHESIZED SPHINGOSINE DERIVATIVE LIPOID MONOMER AND USE OF SAME FOR DELIVERING NUCLEIC ACID | SPHK2, SPHK1, S1PR2 | CYP2D6 4037/4885SPHK1 2/4885LMNA 220/4885 |
| US-20110150984-A1 | METHODS OF INCREASING THE BIOAVAILABILITY AND/OR CELLULAR UPDATE OF DRUGS | NPC1L1, SGMS2, SGMS1 | CYP2D6 744/4885SPHK1 23/4885LMNA 864/4885 |
| US-20070082855-A1 | Pharmaceutical formulations employing short-chain sphingolipids and their use | SGMS1, SGMS2, CERT1 | CYP2D6 1096/4885SPHK1 17/4885LMNA 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.